Tianxing Zhou. "A phase 2 study of STING agonist ADU-S100 combined with a CLDN18.2 bispecific antibody in patients with advanced pancreatic cancer.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.2_suppl.749